Items where authors include "Lambe, T."

Article

Neale, I. orcid.org/0000-0001-7026-7390, Ali, M. orcid.org/0000-0003-0170-7182, Kronsteiner, B. orcid.org/0000-0003-0867-2867 et al. (26 more authors) (2023) CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study. mBio, 14 (5). e0121223. ISSN 2161-2129

Hornsby, H. orcid.org/0000-0002-6657-9743, Nicols, A.R. orcid.org/0000-0002-1813-3819, Longet, S. orcid.org/0000-0001-5026-431X et al. (40 more authors) (2023) Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nature Communications, 14 (1). 5065. ISSN 2041-1723

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine. ISSN 1078-8956

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29 (7). pp. 1760-1774. ISSN 1078-8956

Shaw, R.H., Greenland, M., Stuart, A.S.V. et al. (37 more authors) (2023) Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, 86 (6). pp. 574-583. ISSN 0163-4453

Dijokaite-Guraliuc, A., Das, R., Zhou, D. et al. (44 more authors) (2023) Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. Cell Reports, 42 (4). 112271. ISSN 2211-1247

Moore, S.C. orcid.org/0000-0001-8610-2806, Kronsteiner, B., Longet, S. et al. (61 more authors) (2023) Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens. Med, 4 (3). 191-215.e9. ISSN 2666-6340

Huo, J., Dijokaite-Guraliuc, A., Liu, C. et al. (34 more authors) (2023) A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Cell Reports, 42 (1). 111903. ISSN 2211-1247

Mentzer, A.J. orcid.org/0000-0002-4502-2209, O’Connor, D. orcid.org/0000-0002-6902-9886, Bibi, S. et al. (66 more authors) (2023) Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 29 (1). pp. 147-157. ISSN 1078-8956

Shaw, R.H., Liu, X., Stuart, A.S.V. et al. (81 more authors) (2022) Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine, 10 (11). pp. 1049-1060. ISSN 2213-2600

Stuart, A.S.V., Shaw, R.H., Liu, X. et al. (40 more authors) (2022) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, 399 (10319). pp. 36-49. ISSN 0140-6736

Ramasamy, M.N., Minassian, A.M., Ewer, K.J. et al. (418 more authors) (2020) Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396 (10267). pp. 1979-1993. ISSN 0140-6736

Coughlan, L., Sridhar, S., Payne, R. orcid.org/0000-0002-8490-671X et al. (16 more authors) (2018) Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine, 29. pp. 146-154. ISSN 2352-3964